WallStSmart

Establishment Labs Holdings Inc (ESTA)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 28548% more annual revenue ($65.77B vs $229.58M). MRK leads profitability with a 13.6% profit margin vs -19.1%. MRK earns a higher WallStSmart Score of 50/100 (D+).

ESTA

Avoid

30

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 4.0Quality: 5.3
Piotroski: 4/9

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ESTASignificantly Overvalued (-17.9%)

Margin of Safety

-17.9%

Fair Value

$61.70

Current Price

$74.31

$12.61 premium

UndervaluedFair: $61.70Overvalued
MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ESTA1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
44.7%10/10

Revenue surging 44.7% year-over-year

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

ESTA4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
148.6x2/10

Trading at 148.6x book value

Return on EquityProfitability
-295.9%2/10

ROE of -295.9% — below average capital efficiency

Free Cash FlowQuality
$-6.16M2/10

Negative free cash flow — burning cash

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ESTA

The strongest argument for ESTA centers on Revenue Growth. Revenue growth of 44.7% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : ESTA

The primary concerns for ESTA are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 17.86 is elevated, increasing financial risk.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

ESTA profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.

ESTA carries more volatility with a beta of 1.12 — expect wider price swings.

ESTA is growing revenue faster at 44.7% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Establishment Labs Holdings Inc

HEALTHCARE · MEDICAL DEVICES · USA

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for cosmetic and reconstructive plastic surgery. The company is headquartered in Alajuela, Costa Rica.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?